Latest Underwriting News

Centuria Capital Group has launched the retail component of its $100 million entitlement offer, aiming to raise approximately $35 million. The equity raising supports expansion in AI infrastructure and real estate funds management.

Qualitas Limited has upgraded its long-term Australian funds management EBITDA margin target from over 50% to more than 60%, driven by operational efficiencies and a proprietary AI platform designed to streamline investment processes.

Kingston Resources launches a $8.47 million rights issue at a 12.5% discount, backed by a $4.4 million placement, to finance a major drilling campaign and plant expansion at Mineral Hill following the closure of its Pearse South open pit.

VRX Silica Limited has successfully closed a renounceable rights issue, securing $2.86 million to fund key developments at its Arrowsmith North and Muchea silica sand projects.

Babylon Pump & Power is steering through a strategic reset with its rental business booming and new funding arrangements in place, aiming to resume trading by August 2026.

Acrow Limited has secured full underwriting for its $10 million Share Purchase Plan, complementing a recent $70 million placement, with shareholder approval pending for any shortfall shares.

Beonic Ltd has closed its 5-for-9 renounceable entitlement offer, raising $1.58 million before costs, surpassing initial uptake expectations and reducing underwriting obligations.

NobleOak Life Limited boosted its Embedded Value by 9% to $2.34 per share as of December 2025, driven by strong premium growth and market share gains. The insurer exceeded its FY26 in-force premium guidance with a 16% increase to $538 million.

National Australia Bank updates its interim dividend framework, setting DRP and BSP prices with a partial underwriting by Goldman Sachs for up to AUD 1 billion.

Kingston Resources secures $12.9 million through placement and entitlement offer to fund a 25,000m drilling program and plant expansion at its Mineral Hill polymetallic mine, bolstering cash reserves to $32.3 million ahead of a planned operational restart.

HITIQ Limited secured a Federal Court order extending the quotation period for its HIQOA listed options on the ASX, resolving a regulatory timing issue and validating the delayed admission.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.